Publication detail

Histone deacetylase inhibitors in cancer therapy. A review

HRABĚTA, J. STIBOROVÁ, M. ADAM, V. KIZEK, R. ECKSCHLAGER, T.

Original Title

Histone deacetylase inhibitors in cancer therapy. A review

Type

journal article in Web of Science

Language

English

Original Abstract

Different HDAC inhibitors induce cancer cell death by different mechanisms that include changes in gene expression and alteration of both histone and non-histone proteins. Enhanced histone acetylation in tumors results in modification of expression of genes involved in cell signaling. Inhibition of HDACs causes changed expression in 2-10 % of genes involved in important biological processes. The results of experiments and clinical studies demonstrate that combination of HDAC inhibitors with some anticancer drugs have synergistic or additive effects.

Keywords

chromatin remodeling, histone acetylation, histone deacetylases, histone deacetylase inhibitors, combined treatment modalities, mechanisms of combined treatment

Authors

HRABĚTA, J.; STIBOROVÁ, M.; ADAM, V.; KIZEK, R.; ECKSCHLAGER, T.

RIV year

2014

Released

1. 6. 2014

ISBN

1213-8118

Periodical

Biomedical Papers

Year of study

158

Number

2

State

Czech Republic

Pages from

161

Pages to

169

Pages count

9

BibTex

@article{BUT112436,
  author="Jan {Hraběta} and Marie {Stiborová} and Vojtěch {Adam} and René {Kizek} and Tomáš {Eckschlager}",
  title="Histone deacetylase inhibitors in cancer therapy. A review",
  journal="Biomedical Papers",
  year="2014",
  volume="158",
  number="2",
  pages="161--169",
  doi="10.5507/bp.2013.085",
  issn="1213-8118"
}